



## Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium

September 3, 2024 at 7:00 AM EDT

PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- [Amicus Therapeutics](#) (Nasdaq: FOLD), today announced that five posters across its development programs will be included at the [Society for the Study of Inborn Errors of Metabolism \(SSIEM\) 2024 Annual Symposium](#), being held September 3-6, 2024 in Porto, Portugal.

### **Poster Sessions:**

#### **Fabry Disease:**

**Abstract Title:** *FollowME Fabry Pathfinders registry: patient-reported outcomes in a cohort of patients on migalastat treatment for at least two years* (Poster #21180)

- **Presenter:** Aleš Linhart, D.Sc., Charles University and General University Hospital in Prague, Prague, Czech Republic
- **Poster Session:** Wednesday, September 4, 6:15 – 8:15 p.m. WET
- **Location:** Poster Room, Rosa Mota Pavilion

**Abstract Title:** *Quality of life of migalastat-treated adolescents with Fabry disease: results from the ASPIRE study and open-label extension* (Poster #21202)

- **Presenter:** Amarilis Sanchez-Valle, MD, University of South Florida Health, Tampa, U.S.A.
- **Poster Session:** Wednesday, September 4, 6:15 – 8:15 p.m. WET
- **Location:** Poster Room, Rosa Mota Pavilion

**Abstract Title:** *Exploring the journey of patients living with Fabry disease in Poland* (Poster #20789)

- **Presenter:** Anna Moskal, The Association of Families with Fabry Disease, Wroclaw, Poland
- **Poster Session:** Wednesday, September 4, 6:15 – 8:15 p.m. WET
- **Location:** Poster Room, Rosa Mota Pavilion

#### **Pompe Disease:**

**Abstract Title:** *Post-baseline outcomes of the UK Early Access to Medicines Scheme registry for cipaglucosidase alfa plus miglustat in late-onset Pompe disease* (Poster #20863)

- **Presenter:** Elaine Murphy, MD, University College London Hospitals, London, U.K.
- **Poster Session:** Wednesday, September 4, 6:15 – 8:15 p.m. WET
- **Guided Poster Walk:** Thursday, September 5, 12:10 – 1:40 p.m. WET
- **Location:** Poster Room, Rosa Mota Pavilion

**Abstract Title:** *Miglustat: a first-in-class enzyme stabilizer for late-onset Pompe disease* (Poster #20873)

- **Presenter:** Mark Roberts, MD, Salford Royal NHS Foundation Trust, Greater Manchester Neurosciences Centre, Manchester, U.K.
- **Poster Session:** Wednesday, September 4, 6:15 – 8:15 p.m. WET
- **Location:** Poster Room, Rosa Mota Pavilion

For more information on the SSIEM 2024 Annual Symposium, please visit [ssiem2024.org](https://ssiem2024.org).

### **About Amicus Therapeutics**

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company's website at [www.amicusrx.com](https://www.amicusrx.com), and follow on [X](#) and [LinkedIn](#).

### **CONTACTS:**

#### **Investors:**

Amicus Therapeutics  
Andrew Faughnan  
Vice President, Investor Relations

[afaughnan@amicusrx.com](mailto:afaughnan@amicusrx.com)  
(609) 662-3809

**Media:**

Amicus Therapeutics  
Diana Moore  
Head of Global Corporate Communications  
[dmoore@amicusrx.com](mailto:dmoore@amicusrx.com)  
(609) 662-5079

FOLD-G